General
Preferred name
CLARITHROMYCIN
Synonyms
A-56268 ()
Clarithromycin component of prevpac ()
Febzin XL ()
Zeclar ()
TE-031 ()
Klaricid Paed ()
Naxy ()
Klaricid I.V. ()
Clarithromycine ()
Claritromicina ()
Klaricid 500 ()
Clarithromycin Extended Release ()
Biaxin Xl ()
Klaricid ()
Clarosip ()
Klaricid XL ()
Mycifor XL ()
Klacid ()
Cyllind ()
Xetinin XL ()
Biaxin Xl Pac ()
Klaricid Adult ()
Biaxin ()
Erythromycin, 6-o-methyl- ()
Clarie XL ()
Veclam ()
Macladin ()
NSC-758704 ()
6-o-methylerythromycin ()
Mavid ()
Clarithromycin identity ()
ABBOTT-56268 ()
Clarithromycin-13C-d3 ()
P&D ID
PD001219
CAS
81103-11-9
116836-41-0
2699608-30-3
Tags
available
drug
Approved by
FDA
First approval
1991
Drug indication
Chronic bronchitis
Bacterial infection
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Clarithromycin is a semisynthetic macrolide antibacterial. Structurally it is the 6-O-methyl ether of erythromycin A. (GtoPdb)
PRICE 29
DESCRIPTION Clarithromycin has a broad spectrum of antimicrobial activity. Clarithromycin inhibits the CYP3A4-catalyzed triazolam alpha-hydroxylation with the IC50 (Ki) value of 56 (43) ¦ÌM[2]. Clarithromycin significantly inhibits the HERG potassium current[3].Clarithromycin affects the autophagic flux by impairing the signaling pathway linking hERG1 and PI3K[4].
DESCRIPTION Clarithromycin is a macrolide antibiotic used for the treatment of a wide variety of bacterial infections such as acute otitis, pharyngitis, tonsillitis, respiratory tract infections, uncomplicated skin infections, and helicobacter pylori infection. (Enamine Bioactive Compounds)
DESCRIPTION Clarithromycin (A-56268) is a Macrolide Antimicrobial. The mechanism of action of clarithromycin is as a Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 3A Inhibitor, and P-Glycoprotein Inhibitor. The chemical classification of clarithromycin is Macrolides. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
3
Compound Sets
23
AdooQ Bioactive Compound Library
A10225
Axon Medchem Screening Library
3445
Cayman Chemical Bioactives
19455
26678
ChEMBL Approved Drugs
CHEMBL1741
ChEMBL Drugs
CHEMBL1741
Drug Repurposing Hub
DrugBank
DB01211
DrugBank Approved Drugs
DB01211
DrugCentral
668
DrugCentral Approved Drugs
668
DrugMAP
DM4M1SG
DrugMAP Approved Drugs
DM4M1SG
Enamine Bioactive Compounds
EBC-11206
Enamine BioReference Compounds
Guide to Pharmacology
10903
MedChem Express Bioactive Compound Library
HY-17508
NCATS Inxight Approved Drugs
H1250JIK0A
NIH Clinical Collections (NCC)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
clarithromycin
TargetMol Bioactive Compound Library
T1434
The Spectrum Collection
External IDs
55
Properties
(calculated by RDKit )
Molecular Weight
747.48
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
4
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
0
cLogP
2.44
TPSA
182.91
Fraction CSP3
0.95
Chiral centers
18.0
Largest ring
14.0
QED
0.27
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Immunology/Inflammation
Metabolism
Microbiology/virology
Anti-infection
Metabolic Enzyme/Protease
Indication
pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis
Disease Area
otolaryngology, pulmonary, infectious disease
Target
CYP3A4
antibiotic
Bacterial
Cytochrome P450
P450 (e.g. CYP17)
50S ribosome
MRP1
MOA
bacterial 50S ribosomal subunit inhibitor
Therapeutic Class
Antibiotics
Source data